Global Gene Therapy for Neurodegenerative Diseases Supply, Demand and Key Producers, 2023-2029
The global Gene Therapy for Neurodegenerative Diseases market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
This report studies the global Gene Therapy for Neurodegenerative Diseases demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Gene Therapy for Neurodegenerative Diseases, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gene Therapy for Neurodegenerative Diseases that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Gene Therapy for Neurodegenerative Diseases total market, 2018-2029, (USD Million)
Global Gene Therapy for Neurodegenerative Diseases total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Gene Therapy for Neurodegenerative Diseases total market, key domestic companies and share, (USD Million)
Global Gene Therapy for Neurodegenerative Diseases revenue by player and market share 2018-2023, (USD Million)
Global Gene Therapy for Neurodegenerative Diseases total market by Type, CAGR, 2018-2029, (USD Million)
Global Gene Therapy for Neurodegenerative Diseases total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Gene Therapy for Neurodegenerative Diseases market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Voyager Therapeutics, Uniqure N.V., Axovant Gene Therapies, Novartis Ag, Amicus Therapeutics, Regenxbio Inc., Sarepta Therapeutics, Gensight Biologics and Krystal Biotech, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Gene Therapy for Neurodegenerative Diseases market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Gene Therapy for Neurodegenerative Diseases Market, By Region:
1. How big is the global Gene Therapy for Neurodegenerative Diseases market?
2. What is the demand of the global Gene Therapy for Neurodegenerative Diseases market?
3. What is the year over year growth of the global Gene Therapy for Neurodegenerative Diseases market?
4. What is the total value of the global Gene Therapy for Neurodegenerative Diseases market?
5. Who are the major players in the global Gene Therapy for Neurodegenerative Diseases market?
This report studies the global Gene Therapy for Neurodegenerative Diseases demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Gene Therapy for Neurodegenerative Diseases, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gene Therapy for Neurodegenerative Diseases that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Gene Therapy for Neurodegenerative Diseases total market, 2018-2029, (USD Million)
Global Gene Therapy for Neurodegenerative Diseases total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Gene Therapy for Neurodegenerative Diseases total market, key domestic companies and share, (USD Million)
Global Gene Therapy for Neurodegenerative Diseases revenue by player and market share 2018-2023, (USD Million)
Global Gene Therapy for Neurodegenerative Diseases total market by Type, CAGR, 2018-2029, (USD Million)
Global Gene Therapy for Neurodegenerative Diseases total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Gene Therapy for Neurodegenerative Diseases market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Voyager Therapeutics, Uniqure N.V., Axovant Gene Therapies, Novartis Ag, Amicus Therapeutics, Regenxbio Inc., Sarepta Therapeutics, Gensight Biologics and Krystal Biotech, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Gene Therapy for Neurodegenerative Diseases market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Gene Therapy for Neurodegenerative Diseases Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Gene Replacement Therapy
- Gene Silencing Therapy
- Gene Editing Therapy
- Enzyme Replacement Therapy
- Hospitals and Clinics
- Research Institutions
- Biotechnology Companies
- Others
- Voyager Therapeutics
- Uniqure N.V.
- Axovant Gene Therapies
- Novartis Ag
- Amicus Therapeutics
- Regenxbio Inc.
- Sarepta Therapeutics
- Gensight Biologics
- Krystal Biotech
- Avexis
1. How big is the global Gene Therapy for Neurodegenerative Diseases market?
2. What is the demand of the global Gene Therapy for Neurodegenerative Diseases market?
3. What is the year over year growth of the global Gene Therapy for Neurodegenerative Diseases market?
4. What is the total value of the global Gene Therapy for Neurodegenerative Diseases market?
5. Who are the major players in the global Gene Therapy for Neurodegenerative Diseases market?
1 SUPPLY SUMMARY
1.1 Gene Therapy for Neurodegenerative Diseases Introduction
1.2 World Gene Therapy for Neurodegenerative Diseases Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Gene Therapy for Neurodegenerative Diseases Total Market by Region (by Headquarter Location)
1.3.1 World Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.3 China Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.5 Japan Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.6 South Korea Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.7 ASEAN Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.8 India Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Gene Therapy for Neurodegenerative Diseases Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Gene Therapy for Neurodegenerative Diseases Major Market Trends
2 DEMAND SUMMARY
2.1 World Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.2 World Gene Therapy for Neurodegenerative Diseases Consumption Value by Region
2.2.1 World Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2023)
2.2.2 World Gene Therapy for Neurodegenerative Diseases Consumption Value Forecast by Region (2024-2029)
2.3 United States Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.4 China Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.5 Europe Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.6 Japan Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.7 South Korea Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.8 ASEAN Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.9 India Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
3 WORLD GENE THERAPY FOR NEURODEGENERATIVE DISEASES COMPANIES COMPETITIVE ANALYSIS
3.1 World Gene Therapy for Neurodegenerative Diseases Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Gene Therapy for Neurodegenerative Diseases Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Gene Therapy for Neurodegenerative Diseases in 2022
3.2.3 Global Concentration Ratios (CR8) for Gene Therapy for Neurodegenerative Diseases in 2022
3.3 Gene Therapy for Neurodegenerative Diseases Company Evaluation Quadrant
3.4 Gene Therapy for Neurodegenerative Diseases Market: Overall Company Footprint Analysis
3.4.1 Gene Therapy for Neurodegenerative Diseases Market: Region Footprint
3.4.2 Gene Therapy for Neurodegenerative Diseases Market: Company Product Type Footprint
3.4.3 Gene Therapy for Neurodegenerative Diseases Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Gene Therapy for Neurodegenerative Diseases Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Gene Therapy for Neurodegenerative Diseases Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Gene Therapy for Neurodegenerative Diseases Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Gene Therapy for Neurodegenerative Diseases Consumption Value Comparison
4.2.1 United States VS China: Gene Therapy for Neurodegenerative Diseases Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Gene Therapy for Neurodegenerative Diseases Companies and Market Share, 2018-2023
4.3.1 United States Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023)
4.4 China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue and Market Share, 2018-2023
4.4.1 China Based Gene Therapy for Neurodegenerative Diseases Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023)
4.5 Rest of World Based Gene Therapy for Neurodegenerative Diseases Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Gene Therapy for Neurodegenerative Diseases Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Gene Replacement Therapy
5.2.2 Gene Silencing Therapy
5.2.3 Gene Editing Therapy
5.2.4 Enzyme Replacement Therapy
5.3 Market Segment by Type
5.3.1 World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
5.3.2 World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2029)
5.3.3 World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Gene Therapy for Neurodegenerative Diseases Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospitals and Clinics
6.2.2 Research Institutions
6.2.3 Biotechnology Companies
6.2.4 Others
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
6.3.2 World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2029)
6.3.3 World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Voyager Therapeutics
7.1.1 Voyager Therapeutics Details
7.1.2 Voyager Therapeutics Major Business
7.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
7.1.4 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Voyager Therapeutics Recent Developments/Updates
7.1.6 Voyager Therapeutics Competitive Strengths & Weaknesses
7.2 Uniqure N.V.
7.2.1 Uniqure N.V. Details
7.2.2 Uniqure N.V. Major Business
7.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product and Services
7.2.4 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Uniqure N.V. Recent Developments/Updates
7.2.6 Uniqure N.V. Competitive Strengths & Weaknesses
7.3 Axovant Gene Therapies
7.3.1 Axovant Gene Therapies Details
7.3.2 Axovant Gene Therapies Major Business
7.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product and Services
7.3.4 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Axovant Gene Therapies Recent Developments/Updates
7.3.6 Axovant Gene Therapies Competitive Strengths & Weaknesses
7.4 Novartis Ag
7.4.1 Novartis Ag Details
7.4.2 Novartis Ag Major Business
7.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product and Services
7.4.4 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Novartis Ag Recent Developments/Updates
7.4.6 Novartis Ag Competitive Strengths & Weaknesses
7.5 Amicus Therapeutics
7.5.1 Amicus Therapeutics Details
7.5.2 Amicus Therapeutics Major Business
7.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
7.5.4 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Amicus Therapeutics Recent Developments/Updates
7.5.6 Amicus Therapeutics Competitive Strengths & Weaknesses
7.6 Regenxbio Inc.
7.6.1 Regenxbio Inc. Details
7.6.2 Regenxbio Inc. Major Business
7.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product and Services
7.6.4 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Regenxbio Inc. Recent Developments/Updates
7.6.6 Regenxbio Inc. Competitive Strengths & Weaknesses
7.7 Sarepta Therapeutics
7.7.1 Sarepta Therapeutics Details
7.7.2 Sarepta Therapeutics Major Business
7.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
7.7.4 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Sarepta Therapeutics Recent Developments/Updates
7.7.6 Sarepta Therapeutics Competitive Strengths & Weaknesses
7.8 Gensight Biologics
7.8.1 Gensight Biologics Details
7.8.2 Gensight Biologics Major Business
7.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product and Services
7.8.4 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Gensight Biologics Recent Developments/Updates
7.8.6 Gensight Biologics Competitive Strengths & Weaknesses
7.9 Krystal Biotech
7.9.1 Krystal Biotech Details
7.9.2 Krystal Biotech Major Business
7.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product and Services
7.9.4 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Krystal Biotech Recent Developments/Updates
7.9.6 Krystal Biotech Competitive Strengths & Weaknesses
7.10 Avexis
7.10.1 Avexis Details
7.10.2 Avexis Major Business
7.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Product and Services
7.10.4 Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Avexis Recent Developments/Updates
7.10.6 Avexis Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Gene Therapy for Neurodegenerative Diseases Industry Chain
8.2 Gene Therapy for Neurodegenerative Diseases Upstream Analysis
8.3 Gene Therapy for Neurodegenerative Diseases Midstream Analysis
8.4 Gene Therapy for Neurodegenerative Diseases Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Gene Therapy for Neurodegenerative Diseases Introduction
1.2 World Gene Therapy for Neurodegenerative Diseases Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Gene Therapy for Neurodegenerative Diseases Total Market by Region (by Headquarter Location)
1.3.1 World Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.3 China Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.5 Japan Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.6 South Korea Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.7 ASEAN Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.3.8 India Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Gene Therapy for Neurodegenerative Diseases Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Gene Therapy for Neurodegenerative Diseases Major Market Trends
2 DEMAND SUMMARY
2.1 World Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.2 World Gene Therapy for Neurodegenerative Diseases Consumption Value by Region
2.2.1 World Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2023)
2.2.2 World Gene Therapy for Neurodegenerative Diseases Consumption Value Forecast by Region (2024-2029)
2.3 United States Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.4 China Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.5 Europe Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.6 Japan Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.7 South Korea Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.8 ASEAN Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
2.9 India Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
3 WORLD GENE THERAPY FOR NEURODEGENERATIVE DISEASES COMPANIES COMPETITIVE ANALYSIS
3.1 World Gene Therapy for Neurodegenerative Diseases Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Gene Therapy for Neurodegenerative Diseases Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Gene Therapy for Neurodegenerative Diseases in 2022
3.2.3 Global Concentration Ratios (CR8) for Gene Therapy for Neurodegenerative Diseases in 2022
3.3 Gene Therapy for Neurodegenerative Diseases Company Evaluation Quadrant
3.4 Gene Therapy for Neurodegenerative Diseases Market: Overall Company Footprint Analysis
3.4.1 Gene Therapy for Neurodegenerative Diseases Market: Region Footprint
3.4.2 Gene Therapy for Neurodegenerative Diseases Market: Company Product Type Footprint
3.4.3 Gene Therapy for Neurodegenerative Diseases Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Gene Therapy for Neurodegenerative Diseases Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Gene Therapy for Neurodegenerative Diseases Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Gene Therapy for Neurodegenerative Diseases Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Gene Therapy for Neurodegenerative Diseases Consumption Value Comparison
4.2.1 United States VS China: Gene Therapy for Neurodegenerative Diseases Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Gene Therapy for Neurodegenerative Diseases Companies and Market Share, 2018-2023
4.3.1 United States Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023)
4.4 China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue and Market Share, 2018-2023
4.4.1 China Based Gene Therapy for Neurodegenerative Diseases Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023)
4.5 Rest of World Based Gene Therapy for Neurodegenerative Diseases Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Gene Therapy for Neurodegenerative Diseases Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Gene Replacement Therapy
5.2.2 Gene Silencing Therapy
5.2.3 Gene Editing Therapy
5.2.4 Enzyme Replacement Therapy
5.3 Market Segment by Type
5.3.1 World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
5.3.2 World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2029)
5.3.3 World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Gene Therapy for Neurodegenerative Diseases Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospitals and Clinics
6.2.2 Research Institutions
6.2.3 Biotechnology Companies
6.2.4 Others
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
6.3.2 World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2029)
6.3.3 World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Voyager Therapeutics
7.1.1 Voyager Therapeutics Details
7.1.2 Voyager Therapeutics Major Business
7.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
7.1.4 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Voyager Therapeutics Recent Developments/Updates
7.1.6 Voyager Therapeutics Competitive Strengths & Weaknesses
7.2 Uniqure N.V.
7.2.1 Uniqure N.V. Details
7.2.2 Uniqure N.V. Major Business
7.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product and Services
7.2.4 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Uniqure N.V. Recent Developments/Updates
7.2.6 Uniqure N.V. Competitive Strengths & Weaknesses
7.3 Axovant Gene Therapies
7.3.1 Axovant Gene Therapies Details
7.3.2 Axovant Gene Therapies Major Business
7.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product and Services
7.3.4 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Axovant Gene Therapies Recent Developments/Updates
7.3.6 Axovant Gene Therapies Competitive Strengths & Weaknesses
7.4 Novartis Ag
7.4.1 Novartis Ag Details
7.4.2 Novartis Ag Major Business
7.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product and Services
7.4.4 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Novartis Ag Recent Developments/Updates
7.4.6 Novartis Ag Competitive Strengths & Weaknesses
7.5 Amicus Therapeutics
7.5.1 Amicus Therapeutics Details
7.5.2 Amicus Therapeutics Major Business
7.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
7.5.4 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Amicus Therapeutics Recent Developments/Updates
7.5.6 Amicus Therapeutics Competitive Strengths & Weaknesses
7.6 Regenxbio Inc.
7.6.1 Regenxbio Inc. Details
7.6.2 Regenxbio Inc. Major Business
7.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product and Services
7.6.4 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Regenxbio Inc. Recent Developments/Updates
7.6.6 Regenxbio Inc. Competitive Strengths & Weaknesses
7.7 Sarepta Therapeutics
7.7.1 Sarepta Therapeutics Details
7.7.2 Sarepta Therapeutics Major Business
7.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
7.7.4 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Sarepta Therapeutics Recent Developments/Updates
7.7.6 Sarepta Therapeutics Competitive Strengths & Weaknesses
7.8 Gensight Biologics
7.8.1 Gensight Biologics Details
7.8.2 Gensight Biologics Major Business
7.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product and Services
7.8.4 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Gensight Biologics Recent Developments/Updates
7.8.6 Gensight Biologics Competitive Strengths & Weaknesses
7.9 Krystal Biotech
7.9.1 Krystal Biotech Details
7.9.2 Krystal Biotech Major Business
7.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product and Services
7.9.4 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Krystal Biotech Recent Developments/Updates
7.9.6 Krystal Biotech Competitive Strengths & Weaknesses
7.10 Avexis
7.10.1 Avexis Details
7.10.2 Avexis Major Business
7.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Product and Services
7.10.4 Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Avexis Recent Developments/Updates
7.10.6 Avexis Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Gene Therapy for Neurodegenerative Diseases Industry Chain
8.2 Gene Therapy for Neurodegenerative Diseases Upstream Analysis
8.3 Gene Therapy for Neurodegenerative Diseases Midstream Analysis
8.4 Gene Therapy for Neurodegenerative Diseases Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Gene Therapy for Neurodegenerative Diseases Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Gene Therapy for Neurodegenerative Diseases Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Gene Therapy for Neurodegenerative Diseases Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Gene Therapy for Neurodegenerative Diseases Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Gene Therapy for Neurodegenerative Diseases Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Gene Therapy for Neurodegenerative Diseases Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Gene Therapy for Neurodegenerative Diseases Players in 2022
Table 12. World Gene Therapy for Neurodegenerative Diseases Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Gene Therapy for Neurodegenerative Diseases Company Evaluation Quadrant
Table 14. Head Office of Key Gene Therapy for Neurodegenerative Diseases Player
Table 15. Gene Therapy for Neurodegenerative Diseases Market: Company Product Type Footprint
Table 16. Gene Therapy for Neurodegenerative Diseases Market: Company Product Application Footprint
Table 17. Gene Therapy for Neurodegenerative Diseases Mergers & Acquisitions Activity
Table 18. United States VS China Gene Therapy for Neurodegenerative Diseases Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Gene Therapy for Neurodegenerative Diseases Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)
Table 21. United States Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Gene Therapy for Neurodegenerative Diseases Revenue Market Share (2018-2023)
Table 23. China Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (Province, Country)
Table 24. China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue Market Share (2018-2023)
Table 26. Rest of World Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Gene Therapy for Neurodegenerative Diseases Revenue Market Share (2018-2023)
Table 29. World Gene Therapy for Neurodegenerative Diseases Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (USD Million)
Table 31. World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2029) & (USD Million)
Table 32. World Gene Therapy for Neurodegenerative Diseases Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (USD Million)
Table 34. World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2029) & (USD Million)
Table 35. Voyager Therapeutics Basic Information, Area Served and Competitors
Table 36. Voyager Therapeutics Major Business
Table 37. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
Table 38. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Voyager Therapeutics Recent Developments/Updates
Table 40. Voyager Therapeutics Competitive Strengths & Weaknesses
Table 41. Uniqure N.V. Basic Information, Area Served and Competitors
Table 42. Uniqure N.V. Major Business
Table 43. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product and Services
Table 44. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Uniqure N.V. Recent Developments/Updates
Table 46. Uniqure N.V. Competitive Strengths & Weaknesses
Table 47. Axovant Gene Therapies Basic Information, Area Served and Competitors
Table 48. Axovant Gene Therapies Major Business
Table 49. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product and Services
Table 50. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Axovant Gene Therapies Recent Developments/Updates
Table 52. Axovant Gene Therapies Competitive Strengths & Weaknesses
Table 53. Novartis Ag Basic Information, Area Served and Competitors
Table 54. Novartis Ag Major Business
Table 55. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product and Services
Table 56. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Novartis Ag Recent Developments/Updates
Table 58. Novartis Ag Competitive Strengths & Weaknesses
Table 59. Amicus Therapeutics Basic Information, Area Served and Competitors
Table 60. Amicus Therapeutics Major Business
Table 61. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
Table 62. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Amicus Therapeutics Recent Developments/Updates
Table 64. Amicus Therapeutics Competitive Strengths & Weaknesses
Table 65. Regenxbio Inc. Basic Information, Area Served and Competitors
Table 66. Regenxbio Inc. Major Business
Table 67. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product and Services
Table 68. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Regenxbio Inc. Recent Developments/Updates
Table 70. Regenxbio Inc. Competitive Strengths & Weaknesses
Table 71. Sarepta Therapeutics Basic Information, Area Served and Competitors
Table 72. Sarepta Therapeutics Major Business
Table 73. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
Table 74. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Sarepta Therapeutics Recent Developments/Updates
Table 76. Sarepta Therapeutics Competitive Strengths & Weaknesses
Table 77. Gensight Biologics Basic Information, Area Served and Competitors
Table 78. Gensight Biologics Major Business
Table 79. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product and Services
Table 80. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Gensight Biologics Recent Developments/Updates
Table 82. Gensight Biologics Competitive Strengths & Weaknesses
Table 83. Krystal Biotech Basic Information, Area Served and Competitors
Table 84. Krystal Biotech Major Business
Table 85. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product and Services
Table 86. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Krystal Biotech Recent Developments/Updates
Table 88. Avexis Basic Information, Area Served and Competitors
Table 89. Avexis Major Business
Table 90. Avexis Gene Therapy for Neurodegenerative Diseases Product and Services
Table 91. Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 92. Global Key Players of Gene Therapy for Neurodegenerative Diseases Upstream (Raw Materials)
Table 93. Gene Therapy for Neurodegenerative Diseases Typical Customers
List of Figure
Figure 1. Gene Therapy for Neurodegenerative Diseases Picture
Figure 2. World Gene Therapy for Neurodegenerative Diseases Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Gene Therapy for Neurodegenerative Diseases Total Market Size (2018-2029) & (USD Million)
Figure 4. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 13. Gene Therapy for Neurodegenerative Diseases Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 16. World Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 18. China Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 23. India Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Gene Therapy for Neurodegenerative Diseases by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Gene Therapy for Neurodegenerative Diseases Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Gene Therapy for Neurodegenerative Diseases Markets in 2022
Figure 27. United States VS China: Gene Therapy for Neurodegenerative Diseases Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Gene Therapy for Neurodegenerative Diseases Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type in 2022
Figure 31. Gene Replacement Therapy
Figure 32. Gene Silencing Therapy
Figure 33. Gene Editing Therapy
Figure 34. Enzyme Replacement Therapy
Figure 35. World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2029)
Figure 36. World Gene Therapy for Neurodegenerative Diseases Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 37. World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application in 2022
Figure 38. Hospitals and Clinics
Figure 39. Research Institutions
Figure 40. Biotechnology Companies
Figure 41. Others
Figure 42. Gene Therapy for Neurodegenerative Diseases Industrial Chain
Figure 43. Methodology
Figure 44. Research Process and Data Source
Table 1. World Gene Therapy for Neurodegenerative Diseases Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Gene Therapy for Neurodegenerative Diseases Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Gene Therapy for Neurodegenerative Diseases Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Gene Therapy for Neurodegenerative Diseases Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Gene Therapy for Neurodegenerative Diseases Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Gene Therapy for Neurodegenerative Diseases Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Gene Therapy for Neurodegenerative Diseases Players in 2022
Table 12. World Gene Therapy for Neurodegenerative Diseases Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Gene Therapy for Neurodegenerative Diseases Company Evaluation Quadrant
Table 14. Head Office of Key Gene Therapy for Neurodegenerative Diseases Player
Table 15. Gene Therapy for Neurodegenerative Diseases Market: Company Product Type Footprint
Table 16. Gene Therapy for Neurodegenerative Diseases Market: Company Product Application Footprint
Table 17. Gene Therapy for Neurodegenerative Diseases Mergers & Acquisitions Activity
Table 18. United States VS China Gene Therapy for Neurodegenerative Diseases Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Gene Therapy for Neurodegenerative Diseases Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)
Table 21. United States Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Gene Therapy for Neurodegenerative Diseases Revenue Market Share (2018-2023)
Table 23. China Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (Province, Country)
Table 24. China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue Market Share (2018-2023)
Table 26. Rest of World Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Gene Therapy for Neurodegenerative Diseases Revenue Market Share (2018-2023)
Table 29. World Gene Therapy for Neurodegenerative Diseases Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (USD Million)
Table 31. World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2029) & (USD Million)
Table 32. World Gene Therapy for Neurodegenerative Diseases Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (USD Million)
Table 34. World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2029) & (USD Million)
Table 35. Voyager Therapeutics Basic Information, Area Served and Competitors
Table 36. Voyager Therapeutics Major Business
Table 37. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
Table 38. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Voyager Therapeutics Recent Developments/Updates
Table 40. Voyager Therapeutics Competitive Strengths & Weaknesses
Table 41. Uniqure N.V. Basic Information, Area Served and Competitors
Table 42. Uniqure N.V. Major Business
Table 43. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product and Services
Table 44. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Uniqure N.V. Recent Developments/Updates
Table 46. Uniqure N.V. Competitive Strengths & Weaknesses
Table 47. Axovant Gene Therapies Basic Information, Area Served and Competitors
Table 48. Axovant Gene Therapies Major Business
Table 49. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product and Services
Table 50. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Axovant Gene Therapies Recent Developments/Updates
Table 52. Axovant Gene Therapies Competitive Strengths & Weaknesses
Table 53. Novartis Ag Basic Information, Area Served and Competitors
Table 54. Novartis Ag Major Business
Table 55. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product and Services
Table 56. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Novartis Ag Recent Developments/Updates
Table 58. Novartis Ag Competitive Strengths & Weaknesses
Table 59. Amicus Therapeutics Basic Information, Area Served and Competitors
Table 60. Amicus Therapeutics Major Business
Table 61. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
Table 62. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Amicus Therapeutics Recent Developments/Updates
Table 64. Amicus Therapeutics Competitive Strengths & Weaknesses
Table 65. Regenxbio Inc. Basic Information, Area Served and Competitors
Table 66. Regenxbio Inc. Major Business
Table 67. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product and Services
Table 68. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Regenxbio Inc. Recent Developments/Updates
Table 70. Regenxbio Inc. Competitive Strengths & Weaknesses
Table 71. Sarepta Therapeutics Basic Information, Area Served and Competitors
Table 72. Sarepta Therapeutics Major Business
Table 73. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
Table 74. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Sarepta Therapeutics Recent Developments/Updates
Table 76. Sarepta Therapeutics Competitive Strengths & Weaknesses
Table 77. Gensight Biologics Basic Information, Area Served and Competitors
Table 78. Gensight Biologics Major Business
Table 79. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product and Services
Table 80. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Gensight Biologics Recent Developments/Updates
Table 82. Gensight Biologics Competitive Strengths & Weaknesses
Table 83. Krystal Biotech Basic Information, Area Served and Competitors
Table 84. Krystal Biotech Major Business
Table 85. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product and Services
Table 86. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Krystal Biotech Recent Developments/Updates
Table 88. Avexis Basic Information, Area Served and Competitors
Table 89. Avexis Major Business
Table 90. Avexis Gene Therapy for Neurodegenerative Diseases Product and Services
Table 91. Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 92. Global Key Players of Gene Therapy for Neurodegenerative Diseases Upstream (Raw Materials)
Table 93. Gene Therapy for Neurodegenerative Diseases Typical Customers
List of Figure
Figure 1. Gene Therapy for Neurodegenerative Diseases Picture
Figure 2. World Gene Therapy for Neurodegenerative Diseases Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Gene Therapy for Neurodegenerative Diseases Total Market Size (2018-2029) & (USD Million)
Figure 4. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)
Figure 13. Gene Therapy for Neurodegenerative Diseases Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 16. World Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 18. China Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 23. India Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Gene Therapy for Neurodegenerative Diseases by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Gene Therapy for Neurodegenerative Diseases Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Gene Therapy for Neurodegenerative Diseases Markets in 2022
Figure 27. United States VS China: Gene Therapy for Neurodegenerative Diseases Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Gene Therapy for Neurodegenerative Diseases Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type in 2022
Figure 31. Gene Replacement Therapy
Figure 32. Gene Silencing Therapy
Figure 33. Gene Editing Therapy
Figure 34. Enzyme Replacement Therapy
Figure 35. World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2029)
Figure 36. World Gene Therapy for Neurodegenerative Diseases Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 37. World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application in 2022
Figure 38. Hospitals and Clinics
Figure 39. Research Institutions
Figure 40. Biotechnology Companies
Figure 41. Others
Figure 42. Gene Therapy for Neurodegenerative Diseases Industrial Chain
Figure 43. Methodology
Figure 44. Research Process and Data Source
